Halozyme Therapeutics Inc
HALO59.200USD
+0.180+0.30%
Market hours （ET）Quotes delayed by 15 min
7.29BMarket Cap
15.02P/E TTM
More Details of Halozyme Therapeutics Inc Company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Company Info
Ticker SymbolHALO
Company nameHalozyme Therapeutics Inc
IPO dateJan 30, 2003
CEODr. Helen I. Torley
Number of employees350
Security typeOrdinary Share
Fiscal year-endJan 30
Address12390 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92130
Phone18587948889
Websitehttps://www.halozyme.com/
Ticker SymbolHALO
IPO dateJan 30, 2003
CEODr. Helen I. Torley
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.90K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Ms. Barbara Duncan
Ms. Barbara Duncan
Independent Director
Independent Director
--
--
Ms. Tram Bui
Ms. Tram Bui
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.90K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
168.19M
63.50%
Sales of proprietary products
36.34M
13.72%
Sales of bulk rHuPH20
27.02M
10.20%
Sales-based milestones
15.00M
5.66%
Sales of device partnered products
14.68M
5.54%
Other
3.63M
1.37%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
168.19M
63.50%
Sales of proprietary products
36.34M
13.72%
Sales of bulk rHuPH20
27.02M
10.20%
Sales-based milestones
15.00M
5.66%
Sales of device partnered products
14.68M
5.54%
Other
3.63M
1.37%
Shareholding Stats
Updated: Tue, Jul 29
Updated: Tue, Jul 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
10.39%
State Street Global Advisors (US)
4.91%
Snyder Capital Management, L.P.
2.98%
AllianceBernstein L.P.
2.61%
Other
66.94%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
10.39%
State Street Global Advisors (US)
4.91%
Snyder Capital Management, L.P.
2.98%
AllianceBernstein L.P.
2.61%
Other
66.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.36%
Investment Advisor/Hedge Fund
30.60%
Research Firm
4.57%
Pension Fund
2.37%
Hedge Fund
1.88%
Bank and Trust
1.48%
Sovereign Wealth Fund
1.16%
Individual Investor
1.11%
Insurance Company
0.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1032
125.13M
101.55%
-10.49M
2025Q1
1043
127.91M
103.79%
-10.64M
2024Q4
999
127.73M
103.64%
-14.45M
2024Q3
953
129.39M
102.16%
-10.33M
2024Q2
905
126.24M
99.18%
-14.91M
2024Q1
870
127.71M
100.45%
-13.70M
2023Q4
850
128.82M
97.51%
-11.71M
2023Q3
836
127.73M
96.80%
-13.97M
2023Q2
838
128.24M
97.33%
-12.36M
2023Q1
833
129.53M
95.63%
-10.61M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
14.99M
12.16%
-268.69K
-1.76%
Mar 31, 2025
The Vanguard Group, Inc.
12.80M
10.39%
-451.45K
-3.41%
Mar 31, 2025
State Street Global Advisors (US)
6.05M
4.91%
-1.13M
-15.75%
Mar 31, 2025
Snyder Capital Management, L.P.
3.67M
2.98%
-494.15K
-11.85%
Mar 31, 2025
AllianceBernstein L.P.
3.22M
2.61%
+146.68K
+4.78%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.17M
2.57%
+105.17K
+3.43%
Mar 31, 2025
Macquarie Investment Management
2.67M
2.17%
-231.21K
-7.96%
Mar 31, 2025
Invesco Capital Management LLC
2.42M
1.96%
+628.59K
+35.15%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.03M
1.65%
+95.60K
+4.94%
Mar 31, 2025
Congress Asset Management Company, LLP
2.13M
1.73%
+172.97K
+8.83%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Future Fund Long/Short ETF
3.76%
First Trust NYSE Arca Biotechnology Index Fund
2.71%
Invesco Biotechnology & Genome ETF
2.54%
SPDR S&P Biotech ETF
2.35%
Congress SMid Growth ETF
2.21%
Janus Henderson Small Cap Growth Alpha ETF
2.05%
Invesco S&P MidCap 400 GARP ETF
1.92%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.92%
Virtus LifeSci Biotech Products ETF
1.84%
Alpha Architect US Quantitative Value ETF
1.84%
View more
Future Fund Long/Short ETF
Proportion3.76%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.71%
Invesco Biotechnology & Genome ETF
Proportion2.54%
SPDR S&P Biotech ETF
Proportion2.35%
Congress SMid Growth ETF
Proportion2.21%
Janus Henderson Small Cap Growth Alpha ETF
Proportion2.05%
Invesco S&P MidCap 400 GARP ETF
Proportion1.92%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion1.92%
Virtus LifeSci Biotech Products ETF
Proportion1.84%
Alpha Architect US Quantitative Value ETF
Proportion1.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
